RecruitingNCT05184400

Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer

Identification of New Biomarkers for Patients With Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) - do They Provide New Information Regarding Diagnosis, Treatment Efficacy, Side Effects, or Prognosis?


Sponsor

Herlev and Gentofte Hospital

Enrollment

500 participants

Start Date

Jan 1, 2015

Study Type

OBSERVATIONAL

Conditions

Summary

No validated biomarkers exist that can identify patients with biliary tract cancer at an early stage or predict treatment outcomes. The objective of the present study is to find diagnostic, prognostic and predictive biomarkers.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting blood samples and tissue from patients with biliary tract cancers (cancers of the bile ducts or gallbladder) to search for new biological markers (biomarkers) that could help diagnose these cancers earlier or guide treatment decisions. **You may be eligible if:** - You have been diagnosed with cholangiocarcinoma (bile duct cancer) or gallbladder cancer, confirmed by pathology or imaging - You are being referred or treated for biliary tract cancer - You are able to give informed consent - Prior treatment with chemotherapy or radiation is acceptable **You may NOT be eligible if:** - There are no specific exclusion criteria listed for this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Herlev & Gentofte Hospital

Herlev, Copenhagen, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05184400


Related Trials